million within 18 months. Sitaxentan sodium was later approved in Europe, Canada, and Australia, and was marketed under the brand name Thelin. In 2010, Thelin was voluntarily withdrawn from the market worldwide due to concerns about irreversible liver damage. Other drugs tested in clinical trials Icos tested many other drugs that were not approved. They are: ICM3, an antibody blocking ICAM-3, designed to treat psoriasis. IC14, an antibody blocking CD14, designed to treat sepsis. IC747 and IC776, two LFA-1 antagonists, designed to treat psoriasis. Resiniferatoxin (RTX), a naturally occurring capsaicin analog, designed to treat interstitial cystitis. IC485, a PDE4 inhibitor, designed to treat emphysema, chronic bronchitis, chronic obstructive pulmonary disease, and rheumatoid arthritis. IC83, a CHK-1 inhibitor, designed to enhance chemotherapy. Manufacturing Icos manufactured many antibodies for various companies. In August 2001, the company partnered with Seattle Genetics to manufacture a component of their top experimental antibody drug SGN-15. In November 2001, Icos signed a production agreement with GPC Biotech to manufacture a class of GPC's antibodies that targeted B-cell lymphomas. In January 2002, Icos signed an agreement with Eos Biotechnology, under which Icos would produce Eos's most promising monoclonal antibody candidate, and Eos would have non-exclusive rights to Icos's CHEF1 enhanced mammalian protein production technology. Eos's antibody inhibited angiogenesis (the formation of new blood vessels) and was being researched as a treatment for solid tumors. In October 2003, Icos partnered with Protein Design Labs to manufacture their M200 antibody. Acquisition by Eli Lilly After Icos's experimental drugs failed in clinical trials, Eli Lilly was in a prime position to purchase the company. In October 2006, Eli Lilly announced that it had reached terms to acquire Icos for $2.1 billion, or $32 a share. After receiving pressure from large institutional shareholders as well as proxy advisory firm Institutional Shareholder Services (ISS) suggesting the deal should be rejected, Lilly increased its offer to $2.3 billion or $34 per share, a 6% increase. Again, resistance was voiced by some large shareholders, and ISS advised shareholders against accepting the new offer, which it still deemed insufficient. On January 25, 2007, at a special meeting, 77% of the shareholders voted in support of the acquisition. Eli Lilly closed the transaction to acquire Icos for $2.3 billion on January 29, 2007. As a result of the acquisition, Eli Lilly gained complete ownership of Cialis, and promptly shut down Icos operations and laid off Icos personnel,